SAN DIEGO, Feb. 01, 2024 Erasca, Inc. , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK.
Erasca, Inc. (NASDAQ:ERAS – Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 10,320,000 shares, an increase of 7.2% from the December 31st total of 9,630,000 shares. Approximately 11.2% of the company’s stock are sold short. Based on an average […]
Erasca, Inc. (NASDAQ:ERAS – Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 9,630,000 shares, a decrease of 12.4% from the December 15th total of 10,990,000 shares. Based on an average trading volume of 1,150,000 shares, the […]
Bank of America lowered shares of Erasca (NASDAQ:ERAS – Free Report) from a buy rating to a neutral rating in a report issued on Friday, Marketbeat.com reports. They currently have $6.00 target price on the stock, down from their prior target price of $11.00. Several other equities research analysts also recently issued reports on ERAS. […]
Short Interest in Erasca, Inc (NASDAQ:ERAS) Grows By 21 4% etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.